Group 1 - Purcell & Lefkowitz LLP is investigating Ginkgo Bioworks Holdings, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [3] - The investigation is being conducted on behalf of Ginkgo's shareholders [3] - Shareholders can obtain additional information regarding their rights and options at no cost [1][2]

Given that analysts also expect Ginkgo's top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this point. Meanwhile, on April 10, Ginkgo and Novo Nordisk (NYSE:NVO) disclosed they had expanded their strategic partnership. Under the five-year deal, the firms will seek "to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medicatio ...

According to a press release, Ginkgo aims to "develop and optimize" a microbial strain for a secondary metabolite under Syngenta's pipeline. On a scientific basis, Syngenta's research team has identified the biological solution as a high-potential asset. Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. The agricultural technology (or agritech) market is sizable, having reached a valuation of $23.5 billion in 2022. Further, Zion Mark ...

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can ...

A recovery plan is underway, but it isn't a slam dunk. To say that Ginkgo Bioworks' (DNA -10.03%) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had walked out the door months ago. But with the biotech's ambitious vision for highly automated biopharma manufacturing still unrealized, there may yet be rewards waiting for those who hold on for a bit longer. Or shareholders could just experience even mor ...

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.30 per share and a revenue of $175. ...

Ginkgo Bioworks' Big Team-Up Ginkgo Bioworks: Bad News and Worse News Consequently, if the company continues to run afoul of the NYSE's listing rules, don't be too surprised if the exchange delists Ginkgo Bioworks. Getting kicked off the prestigious NYSE and relegated to the over-thecounter gulag would be a harsh blow for Ginkgo Bioworks and its loyal shareholders. There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money. Ginkgo Biowork ...

Ginkgo Bioworks (NYSE:DNA) layoffs continue today with the cell programming company announcing additional job cuts. Ginkgo Bioworks notes that these layoffs are part of a restructuring plan. This will see some of the job cuts happening in 2025 as it continues to alter its business. However, the initial job cuts will begin this month. More Ginkgo Bioworks Layoffs DNA stock is down 10.6% as of Wednesday afternoon. That comes with over 52 million shares traded. This is above its daily average trading volume of ...

Core Viewpoint - QIAGEN has launched 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its QIAcuity platform, enhancing its capabilities in microbial research and solidifying its leadership in microbial detection and analysis [1][2][3] Product Expansion - The new assays target critical pathogens including Dengue virus Serotypes 1 to 4, Monkeypox clades I and II, and Chikungunya, among others, increasing QIAGEN's total microbial dPCR assay portfolio to over 680 targets [2] - The expansion is part of a broader plan to enhance QIAGEN's wet-lab-tested dPCR assay portfolio, with at least 100 additional dPCR assays expected to be launched throughout 2024 [2] Technological Advancements - QIAGEN's QIAcuity platform utilizes nanoplates to partition samples into thousands of tiny sections, allowing for simultaneous reading of reactions, which enhances sensitivity and specificity in detecting DNA and RNA [4] - The platform reduces processing times from six hours to just two, accommodating various laboratory sizes and throughput requirements [4] Public Health Impact - The new assays are positioned as a timely response to public health crises, enabling precise detection of pathogens and facilitating prompt intervention measures, which can improve patient outcomes [3] Conference Participation - QIAGEN will showcase its expanded digital PCR offerings at the ASM Microbe conference from June 13–17 in Atlanta, Georgia, providing attendees with insights into its microbial research and diagnostic capabilities [5] Research Contributions - QIAGEN will present research on improved extraction methods for total nucleic acid from microbiome samples, emphasizing the importance of mechanical lysis for efficient extraction [6] Collaborative Efforts - A spotlight session on June 16 will highlight QIAGEN's collaboration with the Water Tower Institute and the Public Health Lab Tennessee, focusing on Legionella monitoring using the QIAcuity platform [7]

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again. Rallybio (RLYB) Source: Shu ...